聚乙二醇干扰素
医学
免疫学
病毒学
慢性肝炎
病毒
利巴韦林
作者
Man‐Fung Yuen,Young‐Suk Lim,Ki Tae Yoon,Tien-Huey Lim,Jeong Heo,Pisit Tangkijvanich,Won Young Tak,Vaidehi Thanawala,D. C. Cloutier,Shenghua Mao,Andre Arizpe,Andrea L. Cathcart,Sneha Gupta,Carey Hwang,Edward Gane
标识
DOI:10.1016/s2468-1253(24)00237-1
摘要
Chronic hepatitis B virus (HBV) remains a global concern, with current treatments achieving low rates of HBsAg seroclearance. VIR-2218 (elebsiran), a small interfering RNA agent against HBV transcripts, reduces HBsAg concentrations. We aimed to evaluate the safety and antiviral activity of VIR-2218 with and without pegylated interferon-alpha-2a treatment in participants with chronic HBV.
科研通智能强力驱动
Strongly Powered by AbleSci AI